AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23384372 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of memantine
Number of subjects: 42
Study 23384372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20828791 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 8
Study 20031834 — intervention group
Group type: EXPERIMENTAL
Intervention: Information technology‐supported management program
Number of subjects: 223
Study 20031834 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 223
Study 17163096 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapies including anthracycline- and taxane-based polychemotherapeutics, trastuzumab, with or without endocrine manipulation and with or without PMRT
Number of subjects: 0
Study 17163096 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer agents
Number of subjects: 0
Study 17163096 — intervention group
Group type: COMPARATOR
Intervention: Classic six cycles of intravenous CMF
Number of subjects: 0
Study 15168008 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 400
Study 15168008 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 400
Study 15168008 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 400
Study 12098156 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm sling
Number of subjects: 31
Study 12098156 — intervention group
Group type: COMPARATOR
Intervention: No arm sling
Number of subjects: 31
Study 11776814 — intervention group
Group type: EXPERIMENTAL
Intervention: Zeng Sheng Ping (ZSP)
Number of subjects: 5864
Study 11776814 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinamide
Number of subjects: 5864
Study 11776814 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin
Number of subjects: 5864
Study 11776814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5864
Study 7577314 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*0401 and DRB1*0404 alleles
Number of subjects: 48
Study 7577314 — intervention group
Group type: EXPERIMENTAL
Intervention: DRB1*0101 (DR1)
Number of subjects: 48
Study 7577314 — intervention group
Group type: EXPERIMENTAL
Intervention: DRw6 (DRB1*13,*14)
Number of subjects: 48
Study 7577314 — intervention group
Group type: EXPERIMENTAL
Intervention: heptapeptide motif (positions 67‐74) in the third hypervariable region
Number of subjects: 48
Study 7577314 — intervention group
Group type: EXPERIMENTAL
Intervention: DQA1*0301 and DQB1*0302
Number of subjects: 48
Study 7577314 — intervention group
Group type: EXPERIMENTAL
Intervention: DQA1*0202, DQA1*0501 and DQB1*0201
Number of subjects: 48
Study 7577314 — intervention group
Group type: COMPARATOR
Intervention: DPB1 alleles
Number of subjects: 48
Study 2182240 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 231
Study 2182240 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 231
Study 394302 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg pepstatin, seven times a day
Number of subjects: 60
Study 394302 — intervention group
Group type: COMPARATOR
Intervention: 100 mg placebo, seven times a day
Number of subjects: 60
Study 31434552 — intervention group
Group type: EXPERIMENTAL
Intervention: SNS intervention group (n = 23)
Number of subjects: 68
Study 31434552 — intervention group
Group type: COMPARATOR
Intervention: Education-only intervention group (n = 19)
Number of subjects: 68
Study 31434552 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group (n = 26)
Number of subjects: 68
Study 29430794 — intervention group
Group type: EXPERIMENTAL
Intervention: LSAS-SR (Liebowitz Social Anxiety Scale - Self-Reported)
Number of subjects: 311
Study 29430794 — intervention group
Group type: EXPERIMENTAL
Intervention: LSAS-CA (Liebowitz Social Anxiety Scale - Clinician-Administered)
Number of subjects: 311
Study 26130486 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling intervention
Number of subjects: 95
Study 26130486 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 26130486 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counselling intervention (high risk condition)
Number of subjects: 95
Study 26130486 — intervention group
Group type: COMPARATOR
Intervention: Control group (high risk condition)
Number of subjects: 95
Study 24812894 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Western therapy plus blood cooling and detoxification recipe (BCDR)
Number of subjects: 105
Study 24812894 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive Western therapy
Number of subjects: 105
Study 22894746 — intervention group
Group type: EXPERIMENTAL
Intervention: Home self‐testing for HIV using the OraQuick ADVANCE® HIV‐1/2 Antibody Test on oral fluids
Number of subjects: 1
Study 22894746 — intervention group
Group type: EXPERIMENTAL
Intervention: Home self‐testing for HIV
Number of subjects: 1
Study 20601292 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene (60 mg and 120 mg daily combined)
Number of subjects: 0
Study 18524598 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (n=10)
Number of subjects: 20
Study 18524598 — intervention group
Group type: COMPARATOR
Intervention: Non-trained group (n=10)
Number of subjects: 20
Study 15939067 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil (VOO)
Number of subjects: 40
Study 15939067 — intervention group
Group type: COMPARATOR
Intervention: Refined olive oil (ROO)
Number of subjects: 40
Study 11788467 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli endotoxin (LPS) at doses of 1 or 2 ng/kg
Number of subjects: 19
Study 11788467 — intervention group
Group type: EXPERIMENTAL
Intervention: Escherichia coli endotoxin (LPS)
Number of subjects: 19
Study 12764859 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto CPAP treatment in UPPP group
Number of subjects: 47
Study 12764859 — intervention group
Group type: COMPARATOR
Intervention: Auto CPAP treatment in untreated OSAS group
Number of subjects: 47
Study 12764859 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto CPAP treatment in both groups
Number of subjects: 47
Study 8671329 — intervention group
Group type: EXPERIMENTAL
Intervention: Acridine Orange (AO) staining of spermatozoa
Number of subjects: 103
Study 1875221 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM infusion after CVP
Number of subjects: 92
Study 1875221 — intervention group
Group type: COMPARATOR
Intervention: NABM infusion after CVP
Number of subjects: 92
Study 6125191 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 4
Study 6125191 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 4
Study 6125191 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 4
Study 6125191 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 4
Study 6125191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31957783 — intervention group
Group type: EXPERIMENTAL
Intervention: Software intervention for delirium prevention
Number of subjects: 30
Study 31957783 — intervention group
Group type: EXPERIMENTAL
Intervention: Software usability and accessibility
Number of subjects: 30
Study 31957783 — intervention group
Group type: EXPERIMENTAL
Intervention: Software usage protocol
Number of subjects: 30
Study 30893292 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced-exposure calcineurin inhibitor (CNI, cyclosporine) followed by CNI withdrawal at weeks 7-11 post-transplant
Number of subjects: 95
Study 30893292 — intervention group
Group type: COMPARATOR
Intervention: Standard-exposure cyclosporine
Number of subjects: 95
Study 30893292 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 95
Study 30893292 — intervention group
Group type: COMPARATOR
Intervention: CNI
Number of subjects: 95
Study 30517688 — intervention group
Group type: EXPERIMENTAL
Intervention: Average measured sodium intake (gold standard)
Number of subjects: 2974
Study 30517688 — intervention group
Group type: EXPERIMENTAL
Intervention: Average estimated sodium intake (using Kawasaki formula)
Number of subjects: 2974
Study 30517688 — intervention group
Group type: EXPERIMENTAL
Intervention: First measured sodium intake
Number of subjects: 2974
Study 30517688 — intervention group
Group type: EXPERIMENTAL
Intervention: First estimated sodium intake (using Kawasaki formula)
Number of subjects: 2974
Study 27542702 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth borne expander (hyrax)
Number of subjects: 37
Study 27542702 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 25216650 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 20
Study 25216650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal stimulation
Number of subjects: 20
Study 25216650 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 21739525 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouped lists
Number of subjects: 0
Study 21739525 — intervention group
Group type: COMPARATOR
Intervention: Ungrouped lists
Number of subjects: 0
Study 20672956 — intervention group
Group type: EXPERIMENTAL
Intervention: Healos graft carrier with bone marrow aspirate and local autograft
Number of subjects: 28
Study 20672956 — intervention group
Group type: COMPARATOR
Intervention: Cancellous allograft and local autograft
Number of subjects: 28
Study 17595187 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-MTHF (15 mg/daily for 12 weeks)
Number of subjects: 19
Study 17595187 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study 16123484 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (INH group)
Number of subjects: 47
Study 16123484 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous regular insulin (SC group)
Number of subjects: 47
Study 12145478 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,5-diiodothyropropionic acid (DITPA)
Number of subjects: 19
Study 9989567 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 53
Study 9989567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 9989567 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 53
Study 8548644 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 40
Study 8548644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1550700 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg orally)
Number of subjects: 20
Study 1550700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1550700 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 20
Study 3158146 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 0.3 mg
Number of subjects: 50
Study 3158146 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1-2%
Number of subjects: 50
Study 3158146 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 50
Study 29356761 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF)
Number of subjects: 451
Study 29356761 — intervention group
Group type: COMPARATOR
Intervention: Comparator (COMP: intravenous ertapenem followed by oral amoxicillin/clavulanate)
Number of subjects: 451
Study 26774968 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 17
Study 26774968 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 17
Study 25150638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2916
Study 23158059 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated blood samples from radiosensitive patients (6 Gy)
Number of subjects: 30
Study 23158059 — intervention group
Group type: COMPARATOR
Intervention: Irradiated blood samples from control patients (6 Gy)
Number of subjects: 30
Study 21245996 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin plus placebo (Placebo group)
Number of subjects: 10
Study 21245996 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin plus rebamipide (Rebamipide group)
Number of subjects: 10
Study 18047518 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP + BPO (clindamycin phosphate 10 mg mL(‐1) + benzoyl peroxide 50 mg mL(‐1))
Number of subjects: 130
Study 18047518 — intervention group
Group type: COMPARATOR
Intervention: ADA (adapalene 0.1%)
Number of subjects: 130
Study 16612303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured skin substitutes (CSS)
Number of subjects: 40
Study 16612303 — intervention group
Group type: COMPARATOR
Intervention: Split-thickness skin autograft (AG)
Number of subjects: 40
Study 12860947 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2 on days 1 and 15, LV 20 mg/m2 over 10 to 20 minutes, FU 500 mg/m2 bolus on days 1, 8, and 15 every 28 days
Number of subjects: 41
Study 10853861 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS)
Number of subjects: 20
Study 10853861 — intervention group
Group type: COMPARATOR
Intervention: Control (without ENDS)
Number of subjects: 20
Study 10853861 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS) with nasal decongestant
Number of subjects: 20
Study 10853861 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS) during voluntary hyperpnoea
Number of subjects: 20
Study 9780094 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% intraocular pressure reduction from baseline
Number of subjects: 145
Study 9780094 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 145
Study 7947851 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Times Questionnaire (STQ) group, 79 patients
Number of subjects: 152
Study 7947851 — intervention group
Group type: COMPARATOR
Intervention: Interview group, 73 patients
Number of subjects: 152
Study 3128527 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold air inhalation (2 degrees C)
Number of subjects: 8
Study 3128527 — intervention group
Group type: COMPARATOR
Intervention: Warm air inhalation (32 degrees C)
Number of subjects: 8
Study 29308759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasointestinal tube group
Number of subjects: 100
Study 29308759 — intervention group
Group type: COMPARATOR
Intervention: Nasogastric tube group
Number of subjects: 100
Study 27283935 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation (MiECC)
Number of subjects: 48
Study 27283935 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation with oxygenator (MiECC+F)
Number of subjects: 48
Study 27283935 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 48
Study 24857093 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo)
Number of subjects: 0
Study 23134624 — intervention group
Group type: EXPERIMENTAL
Intervention: Unboosted atazanavir (ATV)
Number of subjects: 369
Study 23134624 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir (ATV/r)
Number of subjects: 369
Study 20215934 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-Based Family Therapy (ABFT)
Number of subjects: 66
Study 20215934 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 66
Study 18612879 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) for three days
Number of subjects: 38
Study 18612879 — intervention group
Group type: COMPARATOR
Intervention: Placebo for three days
Number of subjects: 38
Study 15778874 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana (1.8, 2.8, 3.9% THC)
Number of subjects: 30
Study 15778874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (10, 20 mg)
Number of subjects: 30
Study 15778874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol (30 mg)
Number of subjects: 30
Study 15778874 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana and Dronabinol
Number of subjects: 30
Study 11803324 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic CPB (rectal temperature 35‐37 degrees C, group B)
Number of subjects: 100
Study 11803324 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic CPB (rectal temperature 28‐32 degrees C, group A)
Number of subjects: 100
Study 7841053 — intervention group
Group type: EXPERIMENTAL
Intervention: PC10 immunostaining in stage I malignant tumours
Number of subjects: 98
Study 7841053 — intervention group
Group type: EXPERIMENTAL
Intervention: PC10 immunostaining in advanced ovarian cancer
Number of subjects: 98
Study 7841053 — intervention group
Group type: EXPERIMENTAL
Intervention: PC10 immunostaining in patients with good debulking surgery
Number of subjects: 98
Study 2600001 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 158
Study 2600001 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin and netilmicin
Number of subjects: 158
Study 2600001 — intervention group
Group type: COMPARATOR
Intervention: Non-treated controls
Number of subjects: 158
Study 4969991 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (penicillin V)
Number of subjects: 100
Study 4969991 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenethicillin (Broxil)
Number of subjects: 100
Study 4969991 — intervention group
Group type: EXPERIMENTAL
Intervention: Lincomycin (Lincocin)
Number of subjects: 100
Study 4969991 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study 30730474 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 44
Study 30730474 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 44
Study 27923937 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration Training (WBVT)
Number of subjects: 29
Study 27923937 — intervention group
Group type: COMPARATOR
Intervention: Calisthenics training program
Number of subjects: 29
Study 26238394 — intervention group
Group type: EXPERIMENTAL
Intervention: Living wage intervention including a 350% wage increase and significant workplace improvements.
Number of subjects: 204
Study 26238394 — intervention group
Group type: COMPARATOR
Intervention: Minimum wage at the comparison factory.
Number of subjects: 204
Study 23110786 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 116
Study 23110786 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (5 mg and 12.5 mg)
Number of subjects: 116
Study 23110786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 116
Study 20683707 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly resistance training (n=54)
Number of subjects: 155
Study 20683707 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training (n=51)
Number of subjects: 155
Study 20683707 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly balance and tone classes (n=50)
Number of subjects: 155
Study 19737426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 406
Study 19737426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 17290455 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) 150 IU injected into calf muscles
Number of subjects: 11
Study 17290455 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injected into calf muscles
Number of subjects: 11
Study 15486365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive oral care (teeth and gingiva cleaned after every meal for 1 month)
Number of subjects: 59
Study 15486365 — intervention group
Group type: COMPARATOR
Intervention: Control group (performed their own oral care for 1 month)
Number of subjects: 59
Study 16519422 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor cortex stimulation
Number of subjects: 0
Study 16519422 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 9758291 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin 200 mg once daily
Number of subjects: 312
Study 9758291 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 1 g three times daily
Number of subjects: 312
Study 7532763 — intervention group
Group type: EXPERIMENTAL
Intervention: Anipamil 80 mg once daily
Number of subjects: 19
Study 7532763 — intervention group
Group type: EXPERIMENTAL
Intervention: Anipamil 160 mg once daily
Number of subjects: 19
Study 7532763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2703617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular fibrillation duration of 10 s
Number of subjects: 10
Study 2703617 — intervention group
Group type: COMPARATOR
Intervention: Ventricular fibrillation duration of 20 s
Number of subjects: 10
Study 356718 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol with theophylline and hydroxyzine
Number of subjects: 16
Study 356718 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine with theophylline and hydroxyzine
Number of subjects: 16
Study 356718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 356718 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and hydroxyzine (basic combination)
Number of subjects: 16
Study 31410659 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat therapy
Number of subjects: 370
Study 31410659 — intervention group
Group type: COMPARATOR
Intervention: No application of febuxostat therapy
Number of subjects: 370
Study 28492898 — intervention group
Group type: EXPERIMENTAL
Intervention: selumetinib + docetaxel
Number of subjects: 510
Study 28492898 — intervention group
Group type: COMPARATOR
Intervention: placebo + docetaxel
Number of subjects: 510
Study 23622873 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic atrophy lesions in untreated eyes
Number of subjects: 114
Study 23622873 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of GA
Number of subjects: 114
Study 23622873 — intervention group
Group type: EXPERIMENTAL
Intervention: GA formed in areas previously occupied by drusenoid pigment epithelial detachments
Number of subjects: 114
Study 22676840 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to TCTT campaign messages
Number of subjects: 0